PDIA3 and cancer: Hence, these reports suggest that ERp57 has a critical role in maintaining antitumor immune responses; thus, it may emerge as a potential cancer therapeutic target for the treatment of tumors for which prior treatment failed to induce strong T cell-mediated immune responses.